Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Androbiosys
AddedFeb 19, 2024
UpdatedJun 18, 2026
Androbiosys

Androbiosys

Inactive

Founded in 2005, Androbiosys, Inc. is a biotech firm focused on commercial R&D for prostate disease treatments.

HQ
New York City, NY, US
Founded
2005
Overview
Compare
Fundraising
Employees
Website

Founded in 2005, Androbiosys, Inc. is a biotechnology firm dedicated to the research and development of treatments for prostate diseases. The company's core mission is to advance medical science in the field of urology through innovative biological and physical research. Androbiosys offers a range of commercial R&D services, focusing on developing effective therapies for prostate-related conditions. Their market focus includes healthcare providers, medical researchers, and pharmaceutical companies seeking specialized expertise in prostate disease treatments.

Notable figures associated with Androbiosys include leading scientists and medical researchers in the field of urology. The company has attracted investment from prominent biotech venture capital firms, underscoring its potential and credibility in the industry. Key achievements include several breakthroughs in prostate disease treatment methodologies and successful collaborations with major healthcare institutions. Overall, Androbiosys has made a significant impact by contributing valuable research and innovative solutions to improve patient outcomes in prostate health.

Androbiosys - Similar Companies

Andro Diagnostics logo

Andro Diagnostics

ProstaGene logo

ProstaGene

Uro-1 logo

Uro-1

uro1medical.com

Accunovo Biotechnologies logo

Accunovo Biotechnologies

MetasTx logo

MetasTx

metastx.com

BioHealthonomics logo

BioHealthonomics

BioSurfaces logo

BioSurfaces

biosurfaces.us

Evincis Bio logo

Evincis Bio

Aibios logo

Aibios

aibios.com

UroGen Pharma logo

UroGen Pharma

urogen.com

bioProtonics logo

bioProtonics

bioprotonics.com

Proterixbio logo

Proterixbio

Virxsys logo

Virxsys

Abpro logo

Abpro

MatriSys Bioscience logo

MatriSys Bioscience

matrisysbio.com

Androbiosys - Quick Facts

Who are Androbiosys' competitors?

Companies similar to Androbiosys include Andro Diagnostics, ProstaGene, Uro-1 and Accunovo Biotechnologies.

When was Androbiosys founded?

Androbiosys was founded in 2005.

Where is Androbiosys' headquarters located?

Androbiosys' headquarters is located in New York City, NY, US.

When was Androbiosys' last funding round?

Androbiosys' most recent funding round was for $500k (USD) in January 2009.

How much has Androbiosys raised to-date?

As of Jan 9, 2009, Androbiosys has raised a total of $500k (USD).

Androbiosys - Classification

Ownership
  • Private
Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Software
Customer
  • Enterprise
Main Product
  • Prostate Treatments
Tags
  • Biotech
  • Consulting
  • Healthcare
  • Healthtech
  • Rd